Bissan Al-Lazikani

Affiliations: 
Cancer Therapeutics Unit The Institute of Cancer Research 
Google:
"Bissan Al-Lazikani"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Neeb A, Figueiredo I, Bogdan D, et al. (2024) Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer. Molecular Cancer Therapeutics
di Micco P, Antolin AA, Mitsopoulos C, et al. (2023) canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research. 51: D1212-D1219
Antolin AA, Sanfelice D, Crisp A, et al. (2022) The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use. Nucleic Acids Research
Dolciami D, Villasclaras-Fernandez E, Kannas C, et al. (2022) canSAR chemistry registration and standardization pipeline. Journal of Cheminformatics. 14: 28
Coker EA, Stewart A, Ozer B, et al. (2022) Individualised prediction of drug response and rational combination therapy in NSCLC using artificial intelligence enabled studies of acute phosphoproteomic changes. Molecular Cancer Therapeutics
Müller S, Ackloo S, Al Chawaf A, et al. (2021) Target 2035 - update on the quest for a probe for every protein. Rsc Medicinal Chemistry. 13: 13-21
Antolin AA, Clarke PA, Collins I, et al. (2021) Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology
Mitsopoulos C, Di Micco P, Fernandez EV, et al. (2020) canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research
Darby JF, Vidler LR, Simpson PJ, et al. (2020) Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports. 10: 16000
Zhang C, Stockwell SR, Elbanna M, et al. (2020) Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene
See more...